tetano
Editor, Senior Moderator
Int J Infect Dis
. 2021 Feb 11;S1201-9712(21)00120-X.
doi: 10.1016/j.ijid.2021.02.034. Online ahead of print.
Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay
Gustavo Echeverr?a[SUP] 1 [/SUP], ?ngel Guevara[SUP] 2 [/SUP], Josefina Coloma[SUP] 3 [/SUP], Alison Mera Ruiz[SUP] 4 [/SUP], Mar?a Mercedes Vasquez[SUP] 5 [/SUP], Eduardo Tejera[SUP] 5 [/SUP], Jacobus H de Waard[SUP] 5 [/SUP]
Affiliations
Abstract
Background: Studies of T-cell immune responses against SARS-CoV-2 are important in understanding the immune status of individuals or populations. Here, we use a simple, cheap and rapid whole blood stimulation assay - an Interferon-Gamma Release Assay (IGRA) - to study T-cell immunity to SARS-CoV-2 in convalescent COVID-19 patients and in unexposed healthy contacts from Quito, Ecuador.
Methods: Interferon-gamma (INF-γ) production was measured in the heparinized blood of convalescent and unexposed subjects after stimulation for 24 hours with the SARS-CoV-2 Spike S1 protein, the Receptor Binding Domain (RBD) protein or the Nucleocapsid (NP) protein, respectively. The presence of IgG- RBD protein antibodies in both study groups was determined with an "in-house" ELISA.
Results: As measured with INF-γ production, 80% of the convalescent COVID-19 patients, all IgG-RBD seropositive, had a strong T-cell response. However, unexpectedly, 44% of healthy unexposed healthy controls, all IgG-RBD seronegative, had a strong virus-specific T-cell response with the COVID-19 IGRA, probably because of prior exposure to common cold-causing coronaviruses or other viral or microbial antigens.
Conclusion and discussion: The high percentage of unexposed healthy subjects with a pre-existing immunity suggests that a part of the Ecuadorian population is likely to have SARS-CoV-2 reactive T cells. Given that the IGRA technique is simple, and can be easily scaled up for investigations where high numbers of patients are needed, this COVID-19 IGRA may serve to determine if the T-cell only response represents protective immunity to SARS-CoV-2 infection in a population-based study.
Keywords: COVID-19; ELISPOT; Nucleocapsid; Pre-existing immunity; SARS-CoV-2; Spike protein; T cells; interferon-gamma (IFN-γ) release assay (IGRA); protein.
. 2021 Feb 11;S1201-9712(21)00120-X.
doi: 10.1016/j.ijid.2021.02.034. Online ahead of print.
Pre-existing T-cell immunity to SARS-CoV-2 in unexposed healthy controls in Ecuador, as detected with a COVID-19 Interferon-Gamma Release Assay
Gustavo Echeverr?a[SUP] 1 [/SUP], ?ngel Guevara[SUP] 2 [/SUP], Josefina Coloma[SUP] 3 [/SUP], Alison Mera Ruiz[SUP] 4 [/SUP], Mar?a Mercedes Vasquez[SUP] 5 [/SUP], Eduardo Tejera[SUP] 5 [/SUP], Jacobus H de Waard[SUP] 5 [/SUP]
Affiliations
- PMID: 33582369
- DOI: 10.1016/j.ijid.2021.02.034
Abstract
Background: Studies of T-cell immune responses against SARS-CoV-2 are important in understanding the immune status of individuals or populations. Here, we use a simple, cheap and rapid whole blood stimulation assay - an Interferon-Gamma Release Assay (IGRA) - to study T-cell immunity to SARS-CoV-2 in convalescent COVID-19 patients and in unexposed healthy contacts from Quito, Ecuador.
Methods: Interferon-gamma (INF-γ) production was measured in the heparinized blood of convalescent and unexposed subjects after stimulation for 24 hours with the SARS-CoV-2 Spike S1 protein, the Receptor Binding Domain (RBD) protein or the Nucleocapsid (NP) protein, respectively. The presence of IgG- RBD protein antibodies in both study groups was determined with an "in-house" ELISA.
Results: As measured with INF-γ production, 80% of the convalescent COVID-19 patients, all IgG-RBD seropositive, had a strong T-cell response. However, unexpectedly, 44% of healthy unexposed healthy controls, all IgG-RBD seronegative, had a strong virus-specific T-cell response with the COVID-19 IGRA, probably because of prior exposure to common cold-causing coronaviruses or other viral or microbial antigens.
Conclusion and discussion: The high percentage of unexposed healthy subjects with a pre-existing immunity suggests that a part of the Ecuadorian population is likely to have SARS-CoV-2 reactive T cells. Given that the IGRA technique is simple, and can be easily scaled up for investigations where high numbers of patients are needed, this COVID-19 IGRA may serve to determine if the T-cell only response represents protective immunity to SARS-CoV-2 infection in a population-based study.
Keywords: COVID-19; ELISPOT; Nucleocapsid; Pre-existing immunity; SARS-CoV-2; Spike protein; T cells; interferon-gamma (IFN-γ) release assay (IGRA); protein.